Oligodendroglioma classification: Difference between revisions
Jump to navigation
Jump to search
Sara Mohsin (talk | contribs) |
Sara Mohsin (talk | contribs) |
||
Line 20: | Line 20: | ||
|Diffuse astrocytoma, IDH-mutant | |Diffuse astrocytoma, IDH-mutant | ||
|II | |II | ||
| | |''IDH1/2'' mutation*, ''TP53'' mutation, ''ATRX'' mutation | ||
|- | |- | ||
|Diffuse astrocytoma, IDH-wildtype | |Diffuse astrocytoma, IDH-wildtype | ||
|II | |II | ||
| | |No ''IDH1/2'' mutation | ||
|- | |- | ||
|Anaplastic astrocytoma, IDH-mutant | |Anaplastic astrocytoma, IDH-mutant | ||
|III | |III | ||
| | |''IDH1/2'' mutation*, ''TP53'' mutation, ''ATRX'' mutation | ||
|- | |- | ||
|Anaplastic astrocytoma, IDH-wildtype | |Anaplastic astrocytoma, IDH-wildtype | ||
|III | |III | ||
| | |No ''IDH1/2'' mutation | ||
|- | |- | ||
|Glioblastoma, IDH-mutant | |Glioblastoma, IDH-mutant | ||
|IV | |IV | ||
| | |''IDH1/2'' mutation*, ''TP53'' mutation, ''ATRX'' mutation | ||
|- | |- | ||
|Glioblastoma, IDH-wildtype | |Glioblastoma, IDH-wildtype | ||
|IV | |IV | ||
| | |No ''IDH1/2'' mutation, ''TERT'' promoter mutations | ||
|- | |- | ||
|Glioblastoma, NOS | |Glioblastoma, NOS | ||
|IV | |IV | ||
| | |Genetic testing not done or inconclusive | ||
|- | |- | ||
|Midline diffuse glioma, H3 K27M-mutant | |Midline diffuse glioma, H3 K27M-mutant | ||
|IV | |IV | ||
| | |H3 K27M mutation* | ||
|- | |- | ||
| colspan="2" |'''Oligodendroglial tumors''' | | colspan="2" |'''Oligodendroglial tumors''' | ||
Line 55: | Line 55: | ||
|Oligodendroglioma, IDH-mutant and 1p/19q-codeleted | |Oligodendroglioma, IDH-mutant and 1p/19q-codeleted | ||
|II | |II | ||
| | |''IDH1/2'' mutation*, 1p/19q-codeletion*, no ''ATRX'' mutation, ''TERT''promoter mutations | ||
|- | |- | ||
|Oligodendroglioma, NOS | |Oligodendroglioma, NOS | ||
|II | |II | ||
| | |Genetic testing not done or inconclusive | ||
|- | |- | ||
|Oligoastrocytoma, NOS | |Oligoastrocytoma, NOS | ||
|II | |II | ||
| | |Genetic testing not done or inconclusive | ||
|- | |- | ||
|Anaplastic oligodendroglioma, IDH-mutant and 1p/19q-codeleted | |Anaplastic oligodendroglioma, IDH-mutant and 1p/19q-codeleted | ||
|III | |III | ||
| | |''IDH1/2'' mutation*, 1p/19q-codeletion*, no ''ATRX'' mutation, ''TERT''promoter mutations | ||
|- | |- | ||
|Anaplastic oligodendroglioma, NOS | |Anaplastic oligodendroglioma, NOS | ||
|III | |III | ||
| | |Genetic testing not done or inconclusive | ||
|- | |- | ||
|Anaplastic oligoastrocytoma, NOS | |Anaplastic oligoastrocytoma, NOS | ||
|III | |III | ||
| | |Genetic testing not done or inconclusive | ||
|} | |} | ||
* Oligodendroglioma may be classified according to the 2007 WHO classification of the central nervous system tumors into five subtypes:<ref name="pmid17618441">{{cite journal| author=Louis DN, Ohgaki H, Wiestler OD, Cavenee WK, Burger PC, Jouvet A et al.| title=The 2007 WHO classification of tumours of the central nervous system. | journal=Acta Neuropathol | year= 2007 | volume= 114 | issue= 2 | pages= 97-109 | pmid=17618441 | doi=10.1007/s00401-007-0243-4 | pmc=PMC1929165 | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=17618441 }} </ref> | * Oligodendroglioma may be classified according to the 2007 WHO classification of the central nervous system tumors into five subtypes:<ref name="pmid17618441">{{cite journal| author=Louis DN, Ohgaki H, Wiestler OD, Cavenee WK, Burger PC, Jouvet A et al.| title=The 2007 WHO classification of tumours of the central nervous system. | journal=Acta Neuropathol | year= 2007 | volume= 114 | issue= 2 | pages= 97-109 | pmid=17618441 | doi=10.1007/s00401-007-0243-4 | pmc=PMC1929165 | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=17618441 }} </ref> |
Revision as of 13:34, 1 May 2019
Oligodendroglioma Microchapters |
Diagnosis |
---|
Treatment |
Case Studies |
Oligodendroglioma classification On the Web |
American Roentgen Ray Society Images of Oligodendroglioma classification |
Risk calculators and risk factors for Oligodendroglioma classification |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]Associate Editor(s)-in-Chief: Sara Mohsin, M.D.[2]Sujit Routray, M.D. [3]
Overview
Oligodendroglioma may be classified according to the WHO classification of the central nervous system tumors into five subtypes: oligodendroglioma (OII), anaplastic oligodendroglioma (OIII), oligoastrocytoma (OAII), anaplastic oligoastrocytoma (OAIII), and glioblastoma with oligodendroglioma component (GBMo).
Classification
- As of the 2016 edition of the WHO classification, gliomas are classified based not only on histopathologic appearance but also on well-established molecular parameters
- As of the 2016 update of the World Health Organization (WHO) classification of central nervous system tumors, oligodendroglial tumors are now more narrowly defined by molecular diagnostics to include only those diffuse gliomas harboring both a mutation in isocitrate dehydrogenase type 1 (IDH1) or type 2 (IDH2) and codeletion of chromosomes 1p and 19q.
Tumor classification | Tumor grade | Defining* or characteristic molecular genetic features |
---|---|---|
Astrocytic tumors | ||
Diffuse astrocytoma, IDH-mutant | II | IDH1/2 mutation*, TP53 mutation, ATRX mutation |
Diffuse astrocytoma, IDH-wildtype | II | No IDH1/2 mutation |
Anaplastic astrocytoma, IDH-mutant | III | IDH1/2 mutation*, TP53 mutation, ATRX mutation |
Anaplastic astrocytoma, IDH-wildtype | III | No IDH1/2 mutation |
Glioblastoma, IDH-mutant | IV | IDH1/2 mutation*, TP53 mutation, ATRX mutation |
Glioblastoma, IDH-wildtype | IV | No IDH1/2 mutation, TERT promoter mutations |
Glioblastoma, NOS | IV | Genetic testing not done or inconclusive |
Midline diffuse glioma, H3 K27M-mutant | IV | H3 K27M mutation* |
Oligodendroglial tumors | ||
Oligodendroglioma, IDH-mutant and 1p/19q-codeleted | II | IDH1/2 mutation*, 1p/19q-codeletion*, no ATRX mutation, TERTpromoter mutations |
Oligodendroglioma, NOS | II | Genetic testing not done or inconclusive |
Oligoastrocytoma, NOS | II | Genetic testing not done or inconclusive |
Anaplastic oligodendroglioma, IDH-mutant and 1p/19q-codeleted | III | IDH1/2 mutation*, 1p/19q-codeletion*, no ATRX mutation, TERTpromoter mutations |
Anaplastic oligodendroglioma, NOS | III | Genetic testing not done or inconclusive |
Anaplastic oligoastrocytoma, NOS | III | Genetic testing not done or inconclusive |
- Oligodendroglioma may be classified according to the 2007 WHO classification of the central nervous system tumors into five subtypes:[1]
WHO classification of tumors of CNS | |||||||||||||||||||||||||||||||||||||||||||||
WHO grade II | WHO grade III | WHO grade IV | |||||||||||||||||||||||||||||||||||||||||||
Oligodendroglioma (OII) | |||||||||||||||||||||||||||||||||||||||||||||
Reference
- ↑ Louis DN, Ohgaki H, Wiestler OD, Cavenee WK, Burger PC, Jouvet A; et al. (2007). "The 2007 WHO classification of tumours of the central nervous system". Acta Neuropathol. 114 (2): 97–109. doi:10.1007/s00401-007-0243-4. PMC 1929165. PMID 17618441.